GlassScriptPhysician profile
Althea M Cunningham
NPI 1144595380
$2,294.41
in general payments reported to CMS, 2019-2025
24 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.94 · 2021: $53.19 · 2022: $420 · 2023: $557 · 2024: $780 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.58 | 2022-2025 | |
| Novo Nordisk INC | $295.99 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $244.74 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $209.22 | 2023-2025 | |
| Glaxosmithkline, LLC. | $147.84 | 2019-2024 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Sumitomo Pharma America, INC. | $101.32 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $96.35 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $93.43 | 2023-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $91.00 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.17 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $64.26 | 2022-2024 | Eliquis |
| Amgen INC. | $56.11 | 2021-2025 | Krystexxa, Evenity |
| Bausch Health US, LLC | $52.39 | 2022-2025 | Aplenzin, Wellbutrin |
| Shield Therapeutics INC | $44.47 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $33.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.87 | 2024 | Cologuard Collection Kit |
| Kiniksa Pharmaceuticals International, Plc | $21.15 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $20.55 | 2023 | Arcalyst |
| Sunovion Pharmaceuticals INC. | $19.59 | 2022 | |
| Pfizer INC. | $19.04 | 2023 | |
| Getinge USA Sales, LLC | $17.90 | 2024 | Sensation 7fr. 34cc Iab |
| Vbi Vaccine (Delaware) INC. | $17.71 | 2022 | |
| Merck Sharp & Dohme LLC | $15.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Althea Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.